People

Roy Silverstein, MD, began a 1-year term as president of the American Society of Hematology on December 4 at the organization's 2018 Annual Meeting in San Diego, CA. He is the chairman of the Department of Medicine at the Medical College of Wisconsin (MCW) and the associate director of clinical research at the MCW Cancer Center, both in Milwaukee. He conducts translational research on nonmalignant hematologic diseases, focusing on the molecular, cellular, and genetic causes of thrombosis, neoplastic angiogenesis, and atherosclerosis.

Philip Greenberg, MD, professor of medicine/oncology and immunology at the University of Washingtonand the head of the Program in Immunology at the Fred Hutchinson Cancer Research Center in Seattle, won the Society for Immunotherapy of Cancer 2018 Richard V. Smalley, MD, Memorial Award for his significant contributions to the field of cancer immunotherapy. Greenberg was part of the firstteam to demonstrate that a patient's T cells could be extracted, multiplied in the lab, and reinfused as therapy. He is a scientific founder of Juno Therapeutics and co–editor-in-chief of Cancer Immunology Research.

Albert Bourla, DVM,PhD, began his role as CEO of Pfizer on January 1. He succeeds Ian Read. Bourla joined Pfizer in 1993 as a technical director of the Animal Health Division. Since then, he has held various leadership positions within the company, including president of Innovative Health, president of Global Vaccines, Oncology and Consumer Healthcare, and, most recently, chief operating officer. Bourla also started the Patient and Health Impact group.

For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.